Check out this morning’s top movers from around Wall Street, compiled by The Fly.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
HIGHER –
- Coherus Biosciences (CHRS) up 45% after entering into an asset purchase agreement with Intas Pharmaceuticals for the divestiture of the Udenyca franchise for up to $558.4M
- AT&T (T) up 3% after announcing long-term plans and raising FY24 guidance ahead of its investor day presentation
- Janux Therapeutics (JANX) up 67% after reporting Phase 1a data for JANX007 in metastatic castration-resistant prostate cancer
UP AFTER EARNINGS –
DOWN AFTER EARNINGS –
LOWER –
- U.S. Steel (X) down 6% after President-elect Donald Trump said on his Truth Social platform that he is “totally against” the company’s deal to be acquired by Nippon Steel (NPSCY)
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Coherus Biosciences Sells UDENYCA Franchise to Intas
- Coherus Biosciences agrees to divest UDENYCA franchise for up to $558M
- Coherus Biosciences to sharpen fcous on immuno-oncology portfolio
- Biotech Alert: Searches spiking for these stocks today
- Coherus Biosciences price target lowered to $4 from $8 at Baird